retatrutide ly3437943 parkinson's disease clinical trial suggests drug is safe in humans Retatrutide (LY3437943) | GCGR/GIPR/GLP-1R Agonist

These findings indicate that sustainable lifestyle approaches, such as diet and exercise, could help support the management of post-cessation weight regain, thereby helping to manage SO risk in older adults (Fig

Furthermore, these interventions often rely on single-pathway mechanisms, which do not account for the multifactorial pathogenesis of ocular diseases

The application of ferroptosis is more promising, providing more possibilities for preventing and treating tumors, aging, and inflammation

A robust pipeline of oral GLP-1 agents and next-generation therapies with complementary mechanisms is advancing swiftly, intensifying competition and expanding future treatment possibilities

, ,